Picture of Bruker logo

BRKR — Bruker News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

Bruker Q4 revenue beats estimates on biopharma market recovery

Overview

Scientific instruments firm's Q4 2025 revenue beat analyst expectations despite flat year-over-year growth

Adjusted EPS for Q4 2025 missed analyst estimates

Company expects FY26 revenue growth and significant EPS improvement

Outlook

Bruker expects FY26 revenues of $3.57 to $3.60 bln, up 4% to 5% yoy

Company anticipates FY26 non-GAAP EPS of $2.10 to $2.15, up 15% to 17% yoy

Bruker sees organic revenue growth of 1% to 2% in FY26

Result Drivers

MARKET RECOVERY - Recovery in biopharma and industrial research markets, along with improved semiconductor orders, supported Q4-25 results

COST-SAVING INITIATIVES - Bruker plans to extend cost-saving measures beyond previous targets to enhance operating margins

CURRENCY AND TARIFF HEADWINDS - Academic funding, tariffs, and currency fluctuations posed challenges during 2025

Key Details

MetricBeat/MissActualConsensus Estimate
Q4 RevenueBeat$977.20 mln$960.83 mln (13 Analysts)
Q4 Adjusted EPSMiss$0.59$0.65 (14 Analysts)
Q4 Net Income$29.20 mln
Q4 Gross Profit$449.20 mln
Q4 Operating Expenses$372.90 mln
Q4 Operating Income$76.30 mln
Analyst Coverage The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy", 5 "hold" and 1 "sell" or "strong sell" The average consensus recommendation for the advanced medical equipment & technology peer group is "buy" Wall Street's median 12-month price target for Bruker Corp is $55.00, about 29.6% above its February 11 closing price of $42.43 The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 18 three months ago Press Release: ID:nBw7D8lTta For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com. (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Recent news on Bruker

See all news